Amgen Kicks Off Pembrolizumab Program As It Delivers Q1 Results
ABP234 Proposed Keytruda Rival Is Latest Asset For Amgen’s Biosimilars Business
Amgen has revealed a program for a biosimilar rival to Keytruda, as it reported Q1 results that saw its biosimilars business grow by more than a tenth.
